Balloon-Expandable Valve Outdoes Itself

The objective of this paper recently published in J Am Coll Cardiol Intv was to compare the outcomes of transcatheter aortic valve replacement (TAVR) with the new Sapien 3 Ultra vs. Sapien 3.

La válvula balón expandible se supera a sí misma

Successful implantation was extremely high with both balloon-expandable devices, which also had a very low adverse event rates. However, Sapien Ultra was significantly better than Sapien 3 in terms of paravalvular leak.

Both valves are made of bovine pericardium, with a cobalt-chromium stent plus a low-profile delivery system and high radial force. Sapien Ultra additionally has a polyethylene external skirt, which increases the device height by 40%, providing a 50% bigger contact surface with the native valve so as to improve annular sealing. The release system features differences too.

This registry included all consecutive patients who underwent TAVR with Sapien 3 and Sapien Ultra between 2014 and 2020. Propensity score matching was used to compare both arms.

A total of 310 matched patients were included (155 for each device). After propensity score matching, no difference was detected in baseline clinic characteristics.


Read also: Low-Carb Diet and Coronary Artery Calcium Progression.


Procedures were more frequently done under conscious sedation with Sapien Ultra (97.4% vs. 71.6%; p < 0.001) and pre-dilation was significantly less (42.6% vs. 85.2%; p < 0.001).

In-hospital results, including implantation success (91.6% vs. 95.5%; p = 0.165), major vascular complications (12.3% vs. 11.0%; p = 0.723), and pacemaker implantation (5.8% vs. 4.5%; = 0.608) were comparable between Sapien 3 and Ultra, respectively. 

The postprocedural gradient was similar (13.2 ± 5.7 mmHg vs. 13.1 ± 4.7 mmHg; = 0.829) and so were the rates for moderate and higher paravalvular leak (1.3% vs. 2.7%; p = 0.414).


Read also: AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation.


The significant difference in favor of Sapien Ultra was in mild leak with a rate that was less than half the rate for Sapien 3 (18.7% vs. 43%; p < 0.001).

Conclusion

With excellent results in both devices, adding a polyethylene skirt in the Sapien Ultra device managed to reduce the rate of mild paravalvular leak to less than half.

Original Title: Transcatheter Aortic Valve Replacement With Balloon-Expandable Valves Comparison of SAPIEN 3 Ultra Versus SAPIEN 3.

Reference: Tobias Rheude et al. J Am Coll Cardiol Intv 2020;13:2631–8. https://doi.org/10.1016/j.jcin.2020.07.013.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

Coronary artery disease progression after transcatheter aortic valve replacement: quantitative coronary angiography and Quantitative Flow Ratio analysis

The coexistence of coronary artery disease and severe aortic stenosis is common among patients undergoing transcatheter aortic valve replacement (TAVR). However, the impact of...

UNICORN Technique to Prevent Coronary Obstruction During TAVI: Initial Results From a Multicenter Study

Coronary obstruction is an uncommon but potentially catastrophic complication of transcatheter aortic valve implantation (TAVI), particularly in valve-in-valve procedures, TAV-in-TAV interventions, or in patients...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Clinical and haemodynamic outcomes with contemporary intra- vs. supra-annular valves: The HERA-TAVI Registry

According to the latest European guidelines, transcatheter aortic valve implantation (TAVI) is the recommended treatment for patients aged ≥70 years with symptomatic severe aortic...

Redo-TAVI with SAPIEN 3: 30-Day Outcomes

The indications for transcatheter aortic valve implantation (TAVI) have rapidly expanded to include intermediate- and low-risk patients, extending its use to younger individuals with...

DAPT ≤30 Days After Drug-Coated Balloon Coronary Angioplasty

Drug-coated balloon (DCB) coronary angioplasty without stent implantation has become a well-established alternative in several clinical scenarios, particularly in patients at high bleeding risk...